Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program. J of Skin 2023, 7 (6), s291. https://doi.org/10.25251/skin.7.supp.291.